Email Alert RSS
Volume 14 Issue 4
Jul.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. DOI: 10.12290/xhyxzz.2023-0236
Citation: LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. DOI: 10.12290/xhyxzz.2023-0236
shu

Current Status and Future Prospects of Theranostics with Radiopharmaceuticals

  • Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    LI Fang, E-mail: lifang@pumch.cn

  • Received Date: May 13, 2023
  • Accepted Date: July 17, 2023
  • Available Online: July 19, 2023
  • Issue Publish Date: July 29, 2023
    Graphical Abstract
    • Abstract
  • Nuclear medicine is a novel technique of theranostics that uses radiopharmaceuticals. Nuclear medicine dated back to a century ago. Owing to the development of nuclear medicine devices and radiopharmaceuticals, increasing clinical demand, government support, and global cooperations, nuclear medicine has witnessed a rapid development. Nowadays, nuclear medicine has played an important and unique role in diagnosis and therapy. There are opportunities and challenges in future development of nuclear medicine, and more progress will be made in nuclear medicine imaging, radionuclide therapy, and artificial intelligence.
    • FullText(HTML)
    • References (20)
  • [1]
    Carlsson S. A glance at the history of nuclear medicine[J]. Acta Oncol, 1995, 34: 1095-1102. DOI: 10.3109/02841869509127236
    [2]
    Middlebrooks JT. A Half-Century of Nuclear Medicine[J]. J Nucl Med Technol, 2020, 48: 40S-42S. DOI: 10.2967/jnmt.119.233486
    [3]
    Hutton BF. The origins of SPECT and SPECT/CT[J]. Eur J Nucl Med Mol Imaging, 2014, 41: S3-S16. DOI: 10.1007/s00259-013-2606-5
    [4]
    Verburg FA, Heinzel A, Hänscheid H, et al. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 199-201. DOI: 10.1007/s00259-013-2609-2
    [5]
    Zimmerman RE. Gamma cameras-state of the art[J]. Med Instrum, 1979, 13: 161-164.
    [6]
    Wagner HN Jr. A brief history of positron emission tomography (PET)[J]. Semin Nucl Med, 1998, 28: 213-220. DOI: 10.1016/S0001-2998(98)80027-5
    [7]
    Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. DOI: 10.1056/NEJMoa1607427
    [8]
    Fallah J, Agrawal S, Gittleman H, et al. FDA Approval Summary: Lutetium Lu(177) Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer[J]. Clin Cancer Res, 2023, 29: 1651-1657. DOI: 10.1158/1078-0432.CCR-22-2875
    [9]
    Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium[J]. Thyroid, 2019, 29: 7-26. DOI: 10.1089/thy.2017.0129
    [10]
    Singh S, Hope TA, Bergsland EB, et al. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting[J]. J Natl Cancer Inst, 2023. doi: 10.1093/jnci/djad096.
    [11]
    Ferretti S, Mercinelli C, Marandino L, et al. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs[J]. Res Rep Urol, 2023, 15: 243-259.
    [12]
    Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step[J]. Nucl Med Commun, 2009, 30: 5-15. DOI: 10.1097/MNM.0b013e328313e565
    [13]
    Voutsinas N, Lekperic S, Barazani S, et al. Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques[J]. J Nucl Med, 2018, 59: 1649-1654. DOI: 10.2967/jnumed.116.186346
    [14]
    Velikyan I. Prospective of (68)Ga-radiopharmaceutical development[J]. Theranostics, 2013, 4: 47-80.
    [15]
    Velikyan I. Continued rapid growth in (68) Ga applications: update 2013 to June 2014[J]. J Labelled Comp Radiopharm, 2015, 58: 99-121. DOI: 10.1002/jlcr.3250
    [16]
    Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. DOI: 10.1056/NEJMoa2107322
    [17]
    Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress[J]. Curr Oncol, 2022, 29: 7868-7886. DOI: 10.3390/curroncol29100622
    [18]
    Yordanova A, Ahmadzadehfar H. Combination Therapies with PRRT[J]. Pharmaceuticals (Basel), 2021, 14: 1005. DOI: 10.3390/ph14101005
    [19]
    Nensa F, Demircioglu A, Rischpler C. Artificial Intelligence in Nuclear Medicine[J]. J Nucl Med, 2019, 60: 29S-37S. DOI: 10.2967/jnumed.118.220590
    [20]
    Seifert R, Weber M, Kocakavuk E, et al. Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives[J]. Semin Nucl Med, 2021, 51: 170-177. DOI: 10.1053/j.semnuclmed.2020.08.003
    • Related Articles

  • Related Articles

    [1]ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
    [2]LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei. Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 199-202. DOI: 10.12290/xhyxzz.2021-0715
    [3]CHEN Yue. Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 187-191. DOI: 10.12290/xhyxzz.2021-0557
    [4]LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui. Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 180-186. DOI: 10.12290/xhyxzz.2021-0764
    [5]WANG Guochang, ZHU Zhaohui. Molecular Imaging-guided Precise Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 165-168. DOI: 10.12290/xhyxzz.2021-0773
    [6]Qing-xing LIU, Jie ZANG, Jia-kun REN, Zhao-hui ZHU. Radionuclide Imaging and Therapy of Neuroendocrine Neoplasm by Targeting the Somatostatin Receptor[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 370-376. DOI: 10.3969/j.issn.1674-9081.2020.04.003
    [8]Creasy & Resnik's Maternal-Fetal Medicine:Principles and Practice (7th ed.) (2014)[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 388-388.

  • Cited by

    Periodical cited type(1)

    1. 杜周保，倪翠玲. 生成式人工智能技术赋能档案资源开发利用的逻辑理路与实践策略——以大型公立医院智慧医疗为例. 档案管理. 2024(04): 102-105 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2697) PDF downloads (549) Cited by(4)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close